Loading…
← CockpitCompetitor Analysis › 069620.KS Daewoong PharmOpen in the cockpit ↗

Daewoong Pharm069620.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major
Momentum neutral 52
Mkt cap
$856M
US dollars, full cap
Free float
38%
of shares outstanding
$/day
$1.50M
20-day average traded
Fwd P/E
9.0×
forward earnings
ROIC−WACC
+2.1 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
125 days
23 Mar 2027
Close · KRW₩97,600
1D-2.5%
1W-3.9%
1M-7.0%
3M-21.7%
6M-32.6%
YTD-43.4%
1Y-32.4%
ATR %3.9%
52w lowhigh50.9% off high

What Daewoong Pharm does

Employees: 1,794

Daewoong Pharm at a glance

Size Daewoong Pharm (069620.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $856M, the 263rd largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩97,600 on 18 Nov 2026.

Performance Over six months the shares fell 32.6%, against -18.1% for the median peer and -37.2% for the South Korea market (cap-weighted) — 5th lowest of 19 in its peer set.

Growth Revenue grew 9.2% over the last twelve months (peer median +3.6%); the operating margin is 12.2% (peer median 2.7%).

Valuation It trades at 9.0× forward earnings against a peer median of 24.7× (2nd cheapest of 9).

Capital Return on invested capital runs 2.1 points above its cost of capital (5.0% WACC).

Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026Peer median 79069620.KS 69
Six months, rebased to 100: Daewoong Pharm against the median of its 20 peers (local-currency closes).

Daewoong Pharm financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩1.68T₩1.57T₩1.42T₩1.38T₩1.28T
Revenue growth—+10%+3%+7%—
Gross profit₩871B₩813B₩723B₩682B₩633B
EBITDA₩280B₩246B₩193B₩164B₩134B
Net income₩184B₩196B₩24.7B₩122B₩42.2B
Free cash flow-₩120B-₩42.3B-₩104B₩21.7B₩12.5B
Capital expenditure₩324B₩241B₩229B₩156B₩113B
Total debt₩953B₩829B₩684B₩470B₩497B

Quarterly statements and history in the cockpit →

Daewoong Pharm competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%086450688176CRVS4521688621600771006120PHARMSANOFICONR300267000813603229002082000597AKTS6885536078COLL069620.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Daewoong Pharm is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×0864504521688621600771PHARMSANOFICONR6078COLL069620.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Daewoong Pharm is the large dot.

Daewoong Pharm competitors and peer comparison

How Daewoong Pharm compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Daewoong Pharm against its 20 peers (data as of 18 Nov 2026)
Measure069620.KSPeer medianRank in peer set
1-month return-7.0%-10.3%10th highest of 21
6-month return-32.6%-18.1%5th lowest of 19
Distance from 52-week high-50.9%-40.2%4th lowest of 21
Revenue growth (TTM)+9.2%+3.6%8th highest of 19
Operating margin12.2%2.7%4th highest of 19
Forward P/E9.0×24.7×2nd cheapest of 9
ROIC minus cost of capital+2.1 pp-2.9 pp5th highest of 17
EV / EBITDA7.4×8.8×3rd cheapest of 8
Net debt / EBITDA2.9×-0.3×3rd most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Daewoong Pharm 069620.KSSouth Korea$856M-33%+9%12%9.0×n/an/a
DongKook Pharmaceutical 086450.KSSouth Korea$855M+9%+13%10%14.0×-4.2%+10.6%
Jiangsu Yahong Meditech 688176.SSChina$854M-20%+15%-172%n/an/an/a
Corvus Pharmaceuticals CRVSUnited States$860M-16%n/an/an/an/an/a
Kaken Pharmaceutical 4521.TJapan$860M-8%+5%10%21.4×n/an/a
City Therapeutics CTYUnited States$861Mn/a+388%-442%n/an/an/a
Beijing Sun-Novo Pharmaceutical Research 688621.SSChina$849M-8%-1%-2%29.0×n/an/a
GuangYuYuan Chinese Herbal Medicine 600771.SSChina$866M-26%-6%5%38.3×31.7%+4.2%
SK Discovery 006120.KSSouth Korea$866M+25%+24%3%n/an/an/a
Pharming PHARM.ASNetherlands$867M-6%+2%9%34.9×2.4%+12.4%
Sanofi Consumer Healthcare India SANOFICONR.NSIndia$869M-26%+23%36%28.1×17.7%+22.7%
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
Hunan Er-Kang Pharmaceutical 300267.SZChina$829M-40%-14%-29%n/an/an/a
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%n/an/an/a
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%n/an/an/a
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%n/a27.7%-39.5%
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%n/a-7.6%-0.7%
Aktis Oncology AKTSUnited States$895M-15%+337%-837%n/an/an/a
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%n/a19.4%-6.0%
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%10.4×4.6%+22.5%
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%3.7×-2.6%+20.3%

Questions

Which companies are Daewoong Pharm's closest peers?
The cockpit's peer set: DongKook Pharmaceutical (086450.KS), Jiangsu Yahong Meditech (688176.SS), Corvus Pharmaceuticals (CRVS), Kaken Pharmaceutical (4521.T), City Therapeutics (CTY), Beijing Sun-Novo Pharmaceutical Research (688621.SS), GuangYuYuan Chinese Herbal Medicine (600771.SS), SK Discovery (006120.KS).
Is Daewoong Pharm expensive compared with its peers?
On forward p/e it trades at 9.0× against a peer median of 24.7×, 2nd cheapest of 9 in its peer set.
How has Daewoong Pharm stock performed?
Over six months to 18 Nov 2026 the shares returned -32.6% against -18.1% for the median peer; over one year -32.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.